

Staphylococcus aureus Infections: New Challenges from an Old Pathogen

Zeina A. Kanafani and Vance G. Fowler Jr.

Division of Infectious Diseases, Duke University Medical Center, Durham, NC.

***Staphylococcus aureus* is a versatile organism with several virulent characteristics and resistance mechanisms at its disposal. It is also a significant cause of a wide range of infectious diseases in humans. *S. aureus* often causes life-threatening deep seated infections like bacteremia, endocarditis and pneumonia. While traditionally confined mostly to the hospital setting, methicillin-resistant *S. aureus* (MRSA) is now rapidly becoming rampant in the community. Community-acquired MRSA is particularly significant because of its potential for unchecked spread within households and its propensity for causing serious skin and pulmonary infections. Because of the unfavorable outcome of many MRSA infections with the standard glycopeptide therapy, new antimicrobial agents belonging to various classes have been introduced and have been evaluated in clinical trials for their efficacy in treating resistant staphylococcal infections. A number of preventive strategies have also been suggested to contain the spread of such infections. In this review, we address the recent changes in the epidemiology of *S. aureus* and their impact on the clinical manifestations and management of serious infections. We also discuss new treatment modalities for MRSA infections and emphasize the importance of preventive approaches.**

Key words: *Staphylococcus aureus*. Methicillin resistance. Community-acquired MRSA. Nosocomial infections. Antimicrobial therapy.

Infecciones por *Staphylococcus aureus*: nuevos retos para un viejo patógeno

***Staphylococcus aureus* es un microorganismo versátil con características virulentas y mecanismos de resistencia diversos a su disposición. En seres humanos también es una causa significativa de una amplia variedad de enfermedades infecciosas. Con frecuencia, *S. aureus* provoca infecciones profundas que representan una**

amenaza para la vida, caso de la bacteriemia, endocarditis y neumonía. Aunque tradicionalmente limitado sobre todo a un ámbito hospitalario, en la actualidad *S. aureus* resistente a metilicina (SARM) está aumentando rápidamente en la comunidad. SARM adquirido en la comunidad es de especial importancia debido a la posibilidad de una propagación descontrolada dentro de las familias y a su propensión a originar infecciones cutáneas y pulmonares de gravedad. A causa del desenlace desfavorable de muchas infecciones SARM mediante el tratamiento de referencia con glucopéptidos, se han introducido nuevos fármacos antimicrobianos pertenecientes a diferentes clases y se han evaluado en ensayos clínicos en busca de su eficacia antimicrobiana en el tratamiento de las infecciones estafilocócicas resistentes. Para contener la diseminación de estas infecciones también se han sugerido una serie de estrategias preventivas. En la presente revisión, abordamos los cambios recientes en la epidemiología de *S. aureus* y su impacto en las manifestaciones clínicas y tratamiento de las infecciones de gravedad. También describimos las nuevas modalidades de tratamiento de las infecciones por SARM y hacemos hincapié en la importancia de las medidas preventivas.

Palabras clave: *Staphylococcus aureus*. Resistencia a metilicina. SARM adquirido en la comunidad. Infecciones nosocomiales. Tratamiento antimicrobiano.

Introduction

Despite major advances in the medical arena, *Staphylococcus aureus* remains an important agent of infectious diseases in the human host. Its significance lies in its widespread existence and the broad spectrum of infections it can produce, ranging from inconsequential superficial skin infections to deep-seated life-threatening systemic infections¹. Indeed, some infections caused by *S. aureus*, namely bacteremia and endocarditis, are frequently associated with serious complications and high mortality rates²⁻⁴. The emergence of antibiotic resistance has brought renewed attention to staphylococci⁵. Methicillin-resistant *S. aureus* (MRSA) rates both in hospitalized and ambulatory patients have been escalating, and this resistant phenotype is now considered a major public health problem⁶⁻⁸. Reduced susceptibility to other antimicrobials, including glycopeptides, is being increasingly rec-

Correspondence: Vance G. Fowler Jr., MD.
Division of Infectious Diseases.
Duke University Medical Center.
DUMC Box 3281.
Durham, NC 27710.
E-mail: fowle003@mc.duke.edu

ognized and further complicates the treatment of staphylococcal infections⁹⁻¹¹.

In this review, the authors report on the current trends in the epidemiology, diagnosis, clinical syndromes, and management of *S. aureus* infections in light of the organism's evolving antimicrobial resistance pattern.

Microbiology

Staphylococcus aureus belongs to the *Micrococcaceae* family. It is a nonmotile, non-spore forming, gram-positive coccus that may occur singly, or in pairs, short chains, or grape-like clusters. It is a facultative anaerobe, but grows better under aerobic than anaerobic conditions. The organism produces catalase and coagulase and grows readily on blood and chocolate agar. Colonies measure 1 to 3 mm and typically produce a yellow to golden pigment due to the presence of carotenoids. Most strains produce hemolysis within 24 to 36 hours on horse, sheep, or human blood agar plates¹².

Epidemiology

Worldwide epidemics of *S. aureus* disease have been recognized over the years^{13,14}. Outbreaks have been reported in a variety of settings, including hospitals¹⁵, long-term care facilities¹⁶ and outpatient clinics¹⁷, as well as in the community¹⁸.

Nosocomial Infections

Staphylococci have been long recognized as a problem on hospital wards, and the policy of routine ongoing surveillance for hospital-acquired staphylococcal disease is well justified¹⁹⁻²¹. *S. aureus* is the leading cause of postoperative wound infection, and the second-most frequent cause of nosocomial pneumonia²² and bacteremia²³. Together, *S. aureus* and coagulase-negative staphylococci account for 21% of the estimated 4 million infections acquired annually in United States hospitals²⁴. *S. aureus* nosocomial infections entail great expenditure. Over a two-year period from 2000 to 2001, the average cost of hospitalization in 994 US hospitals for patients with *S. aureus* infections was \$48,834 compared to \$14,141 for patients without such infections²¹. In another study, the mean infection-related costs in patients with prosthetic devices and *S. aureus* bacteremia (SAB) amounted to \$67,439 for hospital-acquired infections and \$37,868 for community-acquired infections²⁵. In addition to the substantial economic burden, significant morbidity and mortality are associated with staphylococcal infections, particularly with invasive infections where mortality rates range between 19% and 34%^{26,27}.

Community-acquired infections

Staphylococcus aureus infections are commonly acquired outside the hospital, particularly among colonized individuals, and have been reported for several decades²⁸⁻³⁰. However, the prevalence of infections caused by MRSA isolates has increased significantly. A Texas-based study in children noted a 14-fold increase in the rate of community-acquired MRSA infections in 2002 compared to previous years³¹. Similarly among adults, the incidence of community-acquired staphylococcal infections varied

from 29% in 1997 to 74% in 2002³². In addition, recent studies have demonstrated a substantial increase in the rate of nasal colonization with MRSA in the community, from 0.8% in 2001 to 9.2% in 2004³³.

Nasal carriage

Staphylococcus aureus may be carried by normal people at various body sites without causing disease. This condition is referred to as colonization to distinguish it from actual infection. It should be noted, however, that colonization frequently precedes infection in susceptible patients³⁴. The anterior nares are the principal sites of colonization with three distinct patterns in the population: persistent carriers (20%), intermittent carriers (60%), or noncarriers (20%)³⁵. Whereas 10%-20% of healthy adults are persistently colonized with *S. aureus*, populations with higher colonization rates include patients with atopic dermatitis (up to 85%)³⁶, as well as surgical patients³⁷, hemodialysis patients³⁸, HIV-infected patients³⁹, and those with intravascular devices⁴⁰. Health care workers who come in contact with patients colonized or infected with *S. aureus* have higher rates of nasal carriage than providers without such contact^{41,42}, and they may develop clinical disease following colonization⁴³. In turn, colonized health care workers can serve as vehicles for the transmission of *S. aureus* to patients. In fact, nosocomial outbreaks are frequently attributed to colonization of the nares and hands of health care workers^{44,45}.

Antimicrobial Resistance Trends

The propensity of *S. aureus* to develop resistance to virtually all the antimicrobial agents available to date has had a monumental impact on clinical infectious diseases. The present day epidemiology of staphylococcal infections has been shaped to a great extent by the rising antibiotic resistance rates commensurate with selective antibiotic pressure.

Resistance to beta-lactams

The first report of penicillinase-producing *S. aureus* was published in 1940, almost a year before penicillin was marketed for clinical use⁴⁶. Since then, beta-lactamase mediated penicillin resistance has been widely described among *S. aureus* isolates, with 80%-93% resistance rates currently reported in the hospital and the community⁴⁷⁻⁴⁹.

Penicillinase-stable cephalosporins and semisynthetic penicillins were introduced in the late 1950s. Once again, *S. aureus* was quick to develop resistance and MRSA isolates were described shortly thereafter⁵⁰. Methicillin resistance has been steadily increasing. According to data from the National Nosocomial Infections Surveillance (NNIS) System, the prevalence of MRSA among hospitalized patients rose from 31.9% in 1996 to 60.7% in 2004 (fig. 1)⁵¹⁻⁵⁵. Similar trends have been observed worldwide, although actual MRSA prevalence is subject to wide geographical variation. For instance, in Europe, MRSA rates as high as 58.0% in Italy and 54.0% in Portugal have been recently reported⁵⁶. In Japan, nearly 70% of *S. aureus* bloodstream isolates in 2001 were methicillin-resistant⁵⁷. On the other hand, Scandinavian countries have consistently noted very low rates of MRSA⁵⁸. Several risk factors have been indepen-




Figure 1. Temporal trends of MRSA rates according to data from the NNIS System. MRSA: methicillin-resistant *S. aureus*; NNIS: National Nosocomial Infection Surveillance; ICU: intensive care unit.

dently associated with nosocomial MRSA colonization and infection, particularly in patients admitted to an intensive care unit (ICU). These include old age, severity of illness, length of ICU stay, multiple antibiotic use, mechanical ventilation, and the use of invasive medical devices (central venous catheters, urinary catheters, feeding tubes)⁵⁹.

Although initially confined to the hospital setting, MRSA isolates are now increasingly encountered in the community. Over the past decade, community-acquired MRSA (CA-MRSA) has quickly become a public health problem of epidemic proportions^{60,61}. NNIS data suggest that in 2004, 50.5% of *S. aureus* isolated from outpatients were methicillin-resistant (fig. 1)⁵³. In addition, a recent meta-analysis reported a 30.2% rate of community-onset MRSA infections from 27 studies. These figures, however, include outpatients with healthcare-associated infections. When applying strict definitions and excluding patients with healthcare-associated risk factors, CA-MRSA rates vary from 18.0 to 25.7 cases per 100,000 population⁶². Multiple outbreaks of invasive infections caused by CA-MRSA have been described⁶³⁻⁶⁵. Susceptible populations include children in day care centers⁸, athletic teams⁶⁶, Native American communities⁶⁷, military personnel⁶⁸, and prison inmates⁶⁹. Patients with CA-MRSA commonly present with suppurative skin infections or necrotizing pneumonia. The ability of the organism to produce such invasive infections has been associated with Pantone-Valentine leukocidin (PVL), a hemolysin encoded by a *pvl* gene located on a mobile phage that can be transmitted to other strains⁷⁰. The presence of *pvl* and other distinct bacterial genetic characteristics, including the presence of staphylococcal chromosomal cassette 4 (SCC_{mec} 4) have been associated with severe cutaneous and pulmonary infections caused by community-acquired MRSA strains^{71,72}. Recent reports document that the epidemiology of CA-MRSA is increasingly blurring with that of hospital-acquired MRSA. A recent report from Atlanta documented that USA300, the most common CA-MRSA clone in the United States, is also a frequent cause of nosocomial and healthcare-associated bacteremia⁷³.

The effect of methicillin resistance on patient outcome has been a matter of intense debate. A number of studies

addressing this issue have noted conflicting results in the setting of various *S. aureus* infections and various patient populations (table 1)⁷⁴⁻⁹⁴. Whether the deleterious effect of MRSA observed in some of these studies is due to inherent virulence of the resistant strains or rather related to failure of vancomycin therapy remains unsettled. The advent of new antimicrobial agents with superior bactericidal activity compared to vancomycin will provide better chances in the future to accurately determine the independent effect of methicillin resistance through careful adjustment for the comorbid conditions of individual patients.

Resistance to glycopeptides

Staphylococcus aureus isolates with intermediate and high-level resistance to glycopeptides have been reported^{95,96}. Different mechanisms account for the two types of resistance. Vancomycin-intermediate *S. aureus* (VISA) harbor mutations that result in thickening of the peptidoglycan layer^{97,98}. Such resistance might be overcome with high doses of vancomycin. Conversely, vancomycin-resistant *S. aureus* (VRSA) have acquired the VanA resistance gene from enterococcal species and therefore do not exhibit a dose-dependent resistance to vancomycin^{95,99}. Although vancomycin resistance rates are still low, the emergence of such strains might be inevitable, especially with the continued pressure posed by intense glycopeptide use.

Diagnosis

Sites of staphylococcal infection are usually teeming with organisms. *S. aureus* grows on ordinary laboratory media and can be readily recognized on Gram stains from most clinical specimens¹⁰⁰. Definitive identification then relies on the tube or slide coagulase test^{101,102}, followed by antibiotic susceptibility testing through disk diffusion¹⁰³ or tube-dilution techniques¹⁰⁴. This method for MRSA identification relies on growing the organism in culture and then performing susceptibility testing; therefore it has a turnaround time of 48-72 hours. Recently developed polymerase chain reaction (PCR) assays provide a more rapid means for identifying MRSA isolates, and are especially valuable in detecting nasal colonization and bloodstream infections¹⁰⁵⁻¹⁰⁷. Similar assays can now detect the *pvl* gene in clinical *S. aureus* isolates^{108,109}.

During outbreaks, phage typing of staphylococci is useful for recognizing the epidemic strain. More recently, molecular typing methods have provided reliable results. These include restriction endonuclease analysis of plasmid DNA¹¹⁰, pulsed-field gel electrophoresis of DNA¹¹¹, and polymerase chain reaction amplification of selected DNA sequences¹¹².

The serological diagnosis of *S. aureus* bacteremia has been evaluated¹¹³. Antibodies to a variety of staphylococcal antigens have been tested including peptidoglycan, teichoic acid, *S. aureus* ultrasonicate, whole *S. aureus* cells, alpha-toxin, lipase and capsular polysaccharide. Whole cell ELISA has been shown to be the most sensitive assay although all tests lacked specificity. Studies suggest that the presence of antibodies to *S. aureus* teichoic acid might indicate a chronic deep seated infection, including endocarditis, chronic osteomyelitis, and septic arthritis, whereas patients with uncomplicated bacteremia, acute os-

TABLE 1. Selection of studies comparing outcomes of patients with *S. aureus* infections with respect to methicillin resistance

Author (reference)	Setting	Findings
Austin et al ⁷⁴	Bacteremia	Trend towards increased attributable mortality with MRSA
Blot et al ⁷⁵	Bacteremia in critically ill patients	Higher attributable mortality with MRSA
Chang et al ⁷⁶	Community-acquired bacteremia	Higher mortality, increased risk of persistent bacteremia and renal insufficiency with MRSA
Combes et al ⁷⁷	Post-sternotomy mediastinitis	No difference in duration of mechanical ventilation or ICU mortality
Cosgrove et al ⁷⁸	Bloodstream infections	Longer hospital stay and higher hospital charges with MRSA
Cowie et al ⁷⁹	Nosocomial infections	Increased hospital stay with MRSA, no effect on mortality
Engemann et al ⁸⁰	Surgical site infections	Increased mortality and hospital charges with MRSA
Harbarth et al ⁸¹	Bacteremia	No effect on in-hospital mortality
Hershow et al ⁸²	Nosocomial infections	No effect on outcome
Kopp et al ⁸³	Various infections	Worse clinical and economic outcomes with MRSA
Lodise et al ⁸⁴	Bacteremia	Increased length of stay and higher costs of hospitalization with MRSA
Martínez-Aguilar et al ⁸⁵	Musculoskeletal infections in children	Greater febrile days and hospital days with MRSA, no effect on final outcome
Marty et al ⁸⁶	Bacteremia in cancer patients	No effect on outcome
Mekontso-Dessap et al ⁸⁷	Post-sternotomy mediastinitis	Worse clinical outcome and higher overall mortality with MRSA
Melzer et al ⁸⁸	Nosocomial bacteremia	Trend towards increased mortality with MRSA, no effect on risk of dissemination
Reed et al ⁸⁹	Bacteremia in HD patients	Higher mortality, longer hospital stay, higher inpatient costs with MRSA
Romero-Vivas et al ⁹⁰	Nosocomial bacteremia	Higher mortality with MRSA
Selvey et al ⁹¹	Nosocomial bacteremia	No difference in mortality
Whitby et al ⁹²	Bacteremia (meta-analysis)	Increased mortality with MRSA
Yoon et al ⁹³	Infective endocarditis	Higher risk of persistent bacteremia and trend towards higher mortality with MRSA
Zahar et al ⁹⁴	Ventilator-associated pneumonia	No effect on ICU or hospital mortality

MRSA: methicillin-resistant *S. aureus*; HD: hemodialysis; ICU: intensive care unit.

teomyelitis, cellulitis, and meningitis frequently have negative titers¹¹⁴.

Clinical Syndromes

Virtually any organ system is prone to infection with *S. aureus*. This review does not present an exhaustive discussion of all the clinical manifestations of staphylococcal infections as these are reviewed elsewhere^{115,116}. We rather focus on systemic infections that have been associated with significant morbidity and mortality and that represent diagnostic and therapeutic challenges for clinical infectious disease specialists.

Bacteremia

Staphylococcus aureus bacteremia is now classified into three categories: hospital-acquired, health care-associated, and community-acquired SAB¹¹⁷. Hospital-acquired and health-care associated infections exhibit similar epidemiological characteristics: both are related to comparable risk factors, such as intravascular devices and comorbid conditions. On the other hand, community-acquired SAB traditionally afflicts intravenous drug users

and otherwise healthy patients with infections at various sites^{118,119}. In addition, hospital-acquired and health-care associated SAB result in significantly greater mortality rates when compared to community-acquired SAB (39%, 29%, and 16%, respectively)¹¹⁷. All three SAB categories have increased considerably over the last decade¹²⁰. From 1980 to 1989, rates of SAB reported to the NNIS system increased by 283% in non-teaching hospitals and 176% in large teaching hospitals¹²¹. By 1998, *S. aureus* had become the second most common bloodstream isolate, contributing to 16% of all hospital-acquired bacteremias¹²². In Finland, Lyttikainen and colleagues documented a 55% increase in the incidence of SAB from 1995 to 2001, primarily in the elderly¹²³. Similarly, community-acquired SAB is being encountered more frequently, particularly with the increasing prevalence of pvl-bearing MRSA isolates in individuals without health-care contact¹²⁴⁻¹²⁶.

Another notable trend in SAB has been the spread of antimicrobial resistance. MRSA rates have recently witnessed a prominent rise as a result of widespread antibiotic use and poor adherence to infection control precautions¹²⁷; approximately 30% of SAB isolates in the United States are now methicillin-resistant¹²². Resistance is more apparent in hospital-acquired (61%) and health-care as-

sociated SAB (52%) than in community-acquired SAB (14%) ($P = .001$)¹¹⁷.

Approximately one-third of patients with SAB develop one or more complications^{118,128-131}. Acute systemic complications typically manifest within 48 hours of diagnosis; these include septic shock, acute respiratory distress syndrome, and disseminated intravascular coagulation. On the other hand, metastatic complications of SAB may only become evident several weeks later. In one large retrospective study, common sites of metastatic disease were joints (36%), kidneys (29%), central nervous system (28%), skin (16%), intervertebral disk (15%), lungs (15%), liver/spleen (13%), bone (11%), and heart valves (8%). Importantly, more than one metastatic site of infection was present in half of the cases¹¹⁸. Distant foci of infection in SAB develop preferentially in populations with certain predisposing conditions: 1) Underlying cardiac disease, such as native valvular abnormalities, congenital heart disease, and prior infective endocarditis¹³²⁻¹³⁴; 2) Prosthetic implants, such as prosthetic valves¹³⁵, intracardiac devices¹³⁶, and orthopedic implants¹³⁷; 3) Community-acquired SAB, due in part to the typically prolonged disease course and duration of bacteremia prior to detection^{138,139}; 4) Old age¹⁴⁰ and comorbid conditions such as hemodialysis¹⁴¹ and infection with the human immunodeficiency virus¹⁴². The absence of the aforementioned risk factors, however, does not exclude the presence of metastatic disease.

Endocarditis

Infective endocarditis (IE) complicates the course of SAB in ~12% of cases^{76,143}. In a recent large cohort of patients, *S. aureus* was the most common cause of native valve endocarditis¹⁴⁴. Recent years have witnessed a rise in the rates of IE due to *S. aureus*¹⁴⁵⁻¹⁴⁸. *S. aureus* is now the leading cause of IE in many parts of the world³. This trend is mostly attributed to the increasing prevalence of healthcare-associated *S. aureus* IE that has accompanied the growing use of interventional procedures, intravascular catheters, and implantable devices¹⁴⁸⁻¹⁵⁰. For instance, Fernandez-Guerrero et al reported a 10-fold increase in the number of cases of hospital-acquired IE (most of which were due to *S. aureus*) from 1978 to 1992 compared to the number of cases occurring from 1960 to 1975¹⁴⁶. The increasing frequency of *S. aureus* IE can also be ascribed to better recognition of the disease through the widespread application of echocardiography in evaluating patients with SAB⁴.

Endocarditis in patients with SAB frequently involves normal cardiac valves and is seldom accompanied by the physical stigmata of IE, rendering the diagnosis of the disease difficult^{149,151}. In fact, reliance solely upon physical examination findings is likely to result in underdiagnosis of *S. aureus* IE in a large number of cases^{132,152}. Because of the difficulty in clinically identifying *S. aureus* IE, the use of echocardiography has been advocated to evaluate patients with SAB. Despite its limited sensitivity in detecting vegetations (64%), transthoracic echocardiography (TTE) is a widely available, non-invasive screening modality in the setting of SAB¹⁵³. Conversely, transesophageal echocardiography (TEE) offers significant advantages over TTE, including higher sensitivity in identifying IE (90%)¹⁵⁴, improved identification of IE complications¹⁵⁵⁻¹⁵⁷, and an enhanced ability to exclude IE in patients with native valves (negative predictive value 100%)^{158,159}.

Whether TTE or TEE should be employed in the initial screening of the patient presenting with SAB remains a controversial issue¹⁶⁰⁻¹⁶². TEE is currently highly favored at our institution for the evaluation of most patients with SAB. The authors believe that TEE is likely to be cost-effective to guide duration of therapy in patients with intravascular catheter-associated SAB¹⁶³ or for patients at higher risk for IE or associated complications¹⁶¹.

Despite early diagnosis and appropriate therapy, IE following SAB is often associated with devastating and life-threatening sequelae. The overall mortality of *S. aureus* IE ranges from 19% to 65%^{118,131,148,149,152}. Other complications include heart failure (20-50%)^{147,149,152}, paravalvular cardiac abscesses (30-40%)^{164,165}, neurological manifestations (30%)^{166,167}, and systemic embolization (40%)¹⁶⁸.

Pneumonia

Staphylococcus aureus is a significant etiologic agent in lower respiratory tract infections that has become increasingly more common in the hospital setting^{169,170}. According to the NNIS System, *S. aureus* was responsible for 20% of nosocomial pneumonias between 1992 and 1997¹⁷⁰. Furthermore, in the European Prevalence of Infection in Intensive Care (EPIC) Study, *S. aureus* was the predominant infective agent, accounting for 31% of microbiologically proven cases of ventilator-associated pneumonia¹⁷¹. Whereas methicillin-susceptible *S. aureus* (MSSA) is typically encountered in early-onset hospital acquired pneumonia (< 5 days after admission), MRSA gains importance in late-onset hospital-acquired pneumonia and particularly in ventilator-associated pneumonia^{22,172}. Nosocomial pneumonia due to MRSA entails significant mortality with rates ranging from 38% to 55%^{173,174}. As with other *S. aureus* infections, whether methicillin resistance by itself contributes to the poor outcome is still a matter of debate^{169,174}.

In addition to its role as a nosocomially acquired pulmonary pathogen, *S. aureus* has recently established itself as an emergent threat in the community. Necrotizing pneumonia and sepsis caused by community-acquired MRSA strains carrying pvl genes are being increasingly recognized^{72,175-179}. Afflicted patients are typically healthy individuals without any healthcare contact. These infections are characterized by multifocal involvement of various organs, including lungs, brain, heart, liver, and kidneys. The pathological feature in the lungs is extensive hemorrhagic necrosis of the pulmonary parenchyma^{72,175,176,178,179}. The mean case fatality rate is noted to be as high as 35%^{72,175,176,178,179}. Mortality seems to be tightly linked to the presence of the pvl gene; in a study of *S. aureus* pneumonia, the mortality rate was 32% in cases with pvl-positive strains, as compared to 6% in those with pvl-negative strains¹⁷⁷.

Staphylococcus aureus pneumonia can present in several different forms, often in parallel with distinct pathophysiological mechanisms: 1) Lobar pneumonia usually occurs as a result of aspiration. Patients are acutely ill with high fevers and productive cough. In severe infections, empyema, abscess formation, cavitation and pneumatoceles may be present^{180,181}; 2) Diffuse interstitial pneumonia usually follows microaspiration and often develops in conjunction with, or following viral pneumonia¹⁸²; 3) Peripheral localized areas of pneumonia are noted with hematogenous seeding of the lungs from septic

emboli secondary either to right-sided endocarditis or to soft tissue or joint infection. In this type of *S. aureus* pneumonia, pleuritic chest pain is a hallmark feature whereas cough and sputum production are less likely^{183,184}.

Novel therapies for MRSA

The use of beta-lactams in the treatment of *S. aureus* infections has been greatly handicapped by the increasing prevalence of MRSA strains. Although vancomycin, the traditional alternative antimicrobial agent, still maintains in-vitro activity against the majority of MRSA isolates, clinical cure rates in serious infections are disheartening. Treatment failure rates exceeding 40% have been recently quoted for SAB¹⁸⁵ and *S. aureus* pneumonia¹⁸⁶ treated with vancomycin. This has kindled great interest in developing new treatment options for MRSA.

Quinupristin/dalfopristin

Quinupristin and dalfopristin belong to the streptogramin class of antibiotics. When combined, these two agents are bactericidal and act in synergy on the 50S ribosomal subunit to inhibit protein synthesis. Quinupristin/dalfopristin is active in-vitro against both MSSA and MRSA¹⁸⁷. The drug is approved by the Food and Drug Administration (FDA) only for the treatment of complicated skin and skin structure infections (cSSSI) due to MSSA¹⁸⁸. However, data from a small controlled trial have suggested that quinupristin/dalfopristin is equivalent to vancomycin in the treatment of catheter-related bacteremia caused by *S. aureus* or coagulase-negative staphylococci (50% clinical and bacteriological responses in both groups)¹⁸⁹. Another study compared in a randomized design quinupristin/dalfopristin to vancomycin in the treatment of nosocomial pneumonia. Although both drugs were comparable in clinical efficacy (56% vs. 58%, respectively), the number of episodes of pneumonia caused by *S. aureus* was relatively small in both arms¹⁹⁰. Quinupristin/dalfopristin has also showed promising results in experimental rat and rabbit models of *S. aureus* endocarditis alone¹⁹¹ or in combination with various antimicrobial agents such as beta-lactams¹⁹², aminoglycosides¹⁹³, rifampin¹⁹⁴, and vancomycin¹⁹⁵. Limited Compassionate Use Registry data are available regarding the use of quinupristin/dalfopristin as a treatment option in patients with serious MRSA infections who are failing or are intolerant of traditional therapy¹⁹⁶. However, the cost, the requirement for administration by central catheter, and the side effect profile have all limited the use of this agent^{197,198}.

Linezolid

Linezolid is an oxazolidinone antimicrobial agent that binds reversibly to the bacterial 23S ribosome, thereby inhibiting protein synthesis. As a result of reversible inhibition, linezolid exhibits bacteriostatic activity against *S. aureus*. A major advantage offered by this new drug is an oral bioavailability of approximately 100%¹⁹⁹. Linezolid is indicated for the treatment of MRSA in the setting of cSSSI including diabetic foot infections without osteomyelitis. It has similar clinical efficacy as vancomycin in such infections but was statistically superior to vancomycin with regard to bacterial eradication in patients with confirmed MRSA at baseline²⁰⁰. More recently, linezolid obtained

FDA approval for the treatment of nosocomial pneumonia^{201,202}. According to a recent pooled analysis of randomized studies, linezolid was not inferior to vancomycin in the treatment of SAB (55% vs. 52%, respectively for overall cure rate)²⁰³. The use of linezolid in MRSA endocarditis has had conflicting results. Although some reports described successful outcomes²⁰⁴⁻²⁰⁶, there have been recent cases of clinical failure (one of which was fatal) with linezolid despite favorable in-vitro susceptibility results^{207,208}. Consequently, the authors do not recommend the use of linezolid in the setting of MRSA endocarditis regardless of the antimicrobial susceptibility of the isolate.

Daptomycin

Daptomycin is a cyclic lipopeptide with rapid bactericidal activity against MRSA. It exerts its action by inserting itself into the bacterial cell membrane. Subsequent events that lead to bacterial cell killing are not fully understood but are thought to involve dissipation of membrane potential. Daptomycin is FDA-approved for the treatment of cSSSI due to *S. aureus* including MRSA. In two distinct Phase III trials in patients with cSSSI, daptomycin resulted in similar success rates as its comparators—semisynthetic penicillin or vancomycin (71.5% and 71.1%, respectively)²⁰⁹. Despite lacking a formal indication, daptomycin is being used considerably in the setting of SAB and *S. aureus* endocarditis^{210,211}. Currently, phase III trials are being conducted to evaluate the efficacy of daptomycin in staphylococcal bloodstream infections. Daptomycin is not indicated in the treatment of pneumonia: the drug is inhibited by pulmonary surfactant²¹² and proved to be inferior to ceftriaxone in a Phase III trial²¹³.

Tigecycline

Tigecycline is a newly introduced glycylicycline derivative with structural homology to tetracyclines. This drug offers broad-spectrum antimicrobial coverage including MRSA through binding to the 30S ribosomal subunit. Tigecycline has received FDA approval for the treatment of cSSSI and complicated intraabdominal infections²¹⁴. In addition, animal models have shown promising results with tigecycline compared to vancomycin in MRSA endocarditis²¹⁵.

Dalbavancin

Dalbavancin is a semisynthetic glycopeptide characterized by a long half-life (9-12 days) that allows once-weekly administration. It exerts its potent activity against MRSA via inhibition of cell wall synthesis. Dalbavancin has shown positive results in Phase III studies in cSSSI²¹⁶ and in a Phase II study in catheter-related bloodstream infections²¹⁷. It is currently awaiting FDA approval for these indications.

Telavancin

Telavancin is an experimental lipoglycopeptide molecule characterized by two mechanisms of action: inhibition of bacterial peptidoglycan synthesis; and alteration of bacterial cell membrane permeability and depolarization. Telavancin exhibits bactericidal in-vitro activity against *S. aureus* isolates including MSSA, MRSA and VISA isolates. In animal infection models, telavancin was efficacious in the treatment of various MRSA infections including soft tissue infections²¹⁸, pneumonia²¹⁹, and endocarditis²²⁰. In Phase II clinical trials, telavancin was compared to stan-

standard therapy (semisynthetic penicillin or vancomycin) in patients with cSSSI²²¹. Data from this study showed that telavancin was equivalent to standard therapy both in clinical cure in the all treated population (79% vs. 80%) as well as in microbiological eradication in the MRSA subgroup (82% vs. 69%; $P = .043$). Phase III trials designed to demonstrate superiority over vancomycin are currently underway in patients with cSSSI, uncomplicated bacteremia, and hospital-acquired pneumonia.

Immunotherapy

Since microbial adherence is central to the initiation and metastatic spread of *S. aureus*, the MSCRAMM (microbial surface components recognizing adhesive matrix molecules) family of bacterial surface adhesin proteins represents an excellent target for the development of novel immunotherapies. Tefibazumab is a humanized IgG monoclonal antibody with high affinity to clumping factor A, an MSCRAMM protein common to virtually all *S. aureus* strains. It interferes with *S. aureus* adherence to extracellular matrix proteins in vitro and may enhance opsonophagocytosis of *S. aureus* by polymorphonuclear leukocytes²²². In an animal model of *S. aureus* IE, addition of tefibazumab to vancomycin significantly increased bacterial clearance from the bloodstream when compared to vancomycin alone ($P < .008$)²²³. The results of a Phase II randomized, double-blind, multi-center clinical study of tefibazumab in patients with SAB were recently presented²²⁴.

Prevention

Nasal decolonization

Since MRSA nasal colonization frequently precedes infection, endeavors to contain the transmission of MRSA have targeted the eradication of nasal carriage in susceptible patients. Studies evaluating this strategy have yielded conflicting results. Cardiothoracic surgery patients who received mupirocin prophylaxis had a lower surgical wound infection rate than historical controls (7.3% vs. 2.8%; $P < .001$)²²⁵. More recently, combining results from two randomized trials in surgical patients suggested that the administration of mupirocin in surgical patients reduced postoperative nosocomial *S. aureus* infections as compared to placebo (RR 0.49, 95% CI 0.29-0.83; number needed to treat 26)^{226,227}. Boelaert et al found a four- to six-fold reduction in SAB rates in hemodialysis patients receiving mupirocin²²⁸. On the other hand, one study in nonsurgical patients failed to show a benefit from mupirocin prophylaxis with respect to rates of nosocomial *S. aureus* infections, in-hospital mortality, and duration of hospitalization²²⁹. Investigators have therefore suggested that a single course of mupirocin may be insufficient in low-risk patients with prolonged exposure²³⁰. In addition to conflicting messages from clinical trials, the emergence of mupirocin-resistance has also been reported^{231,232}.

Vaccination

Staphylococcus aureus Polysaccharide Conjugate Vaccine (StaphVax[®], Nabi Biopharmaceuticals, Rockville, MD) is an investigational polysaccharide conjugate vaccine that presents a novel approach to the prevention of *S. aureus* in-

fections. It consists of type 5 and type 8 capsular polysaccharides, the strains accounting for more than 80% of infections. In one double blinded, placebo-controlled Phase III clinical efficacy trial involving 1804 hemodialysis-dependent patients, StaphVax recipients failed to meet the a priori endpoint of reduction in episodes of *S. aureus* bacteremia at 54 weeks. However, post hoc analysis revealed a 57% reduction in SAB episodes at 10 months compared to placebo recipients ($P = 0.015$)²³³. Based on these findings, a second Phase III confirmatory trial, with modified time points, was undertaken. However, this second trial also failed to meet its primary endpoint. As a result, all clinical trial development and further marketing of StaphVax have been held until assessment of the results is completed.

Infection control strategies

Several studies have established that the transmission of MRSA between patients within the hospital setting occurs to a great extent through health care workers^{44,45}. Consequently, the Centers for Disease Control and Prevention (CDC) recommend the implementation of contact precautions in patients colonized or infected with MRSA²³⁴. Such precautions include the use of private rooms, protective attire for health care workers, and strict adherence to hand hygiene principles. There is abundant evidence to support the efficacy of these infection control programs in reducing the transmission of resistant pathogens within the hospital^{20,235-240}. Although active surveillance for MRSA and preemptive isolation of colonized or infected patients remains an integral part of many hospital infection control programs, observance of infection control guidelines has been suboptimal²⁴¹⁻²⁴³. Hand hygiene practices have been particularly inadequate²⁴⁴⁻²⁴⁷. Accordingly, continuous efforts should be made to improve compliance with isolation and hand hygiene policies to prevent the dire consequences of nosocomial MRSA transmission.

References

1. Lowy FD. *Staphylococcus aureus* infections. N Engl J Med. 1998;339:520-32.
2. Fowler VG Jr, Justice A, Moore C, Benjamin DK Jr, Woods CW, Campbell S, et al. Risk factors for hematogenous complications of intravascular catheter-associated *Staphylococcus aureus* bacteremia. Clin Infect Dis. 2005;40:695-703.
3. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. *Staphylococcus aureus* endocarditis: a consequence of medical progress. JAMA. 2005;293:3012-21.
4. Petti CA, Fowler VG Jr. *Staphylococcus aureus* bacteremia and endocarditis. Cardiol Clin. 2003;21:219-33.
5. Bal AM, Gould IM. Antibiotic resistance in *Staphylococcus aureus* and its relevance in therapy. Expert Opin Pharmacother. 2005;6:2257-69.
6. Calfee DP, Durbin LJ, Germanson TP, Toney DM, Smith EB, Farr BM. Spread of methicillin-resistant *Staphylococcus aureus* (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol. 2003;24:422-6.
7. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). Proc Natl Acad Sci U S A. 2002;99:7687-92.
8. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant *Staphylococcus aureus* in children with no identified predisposing risk. JAMA. 1998;279:593-8.
9. Mangili A, Bica I, Snyderman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant *Staphylococcus aureus* bacteremia. Clin Infect Dis. 2005; 40:1058-60.
10. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in *Staphylococcus aureus*. Infection. 2004;32:315-27.
11. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis. 2005;18:300-5.

12. Wilkinson BJ. Biology. In: Crossley KB, Archer GL, eds. The staphylococci in human disease. New York: Churchill Livingstone; 1997. p. 1-38.
13. Klimek JJ, Marsik FJ, Bartlett RC, Weir B, Shea P, Quintiliani R. Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant *Staphylococcus aureus* at a large community hospital. *Am J Med.* 1976;61:340-5.
14. Lacey RW. Genetic basis, epidemiology, and future significance of antibiotic resistance in *Staphylococcus aureus*: a review. *J Clin Pathol.* 1973;26:899-913.
15. Mallaval FO, Carricajo A, Delavenna F, Recule C, Fonsale N, Manquat G, et al. Detection of an outbreak of methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to glycopeptides in a French hospital. *Clin Microbiol Infect.* 2004;10:459-61.
16. Larssen KW, Jacobsen T, Bergh K, Tvete P, Kvello E, Scheel O. Outbreak of methicillin-resistant *Staphylococcus aureus* in two nursing homes in Central Norway. *J Hosp Infect.* 2005;60:312-6.
17. Lee NE, Taylor MM, Bancroft E, Ruane PJ, Morgan M, McCoy L, et al. Risk factors for community-associated methicillin-resistant *Staphylococcus aureus* skin infections among HIV-positive men who have sex with men. *Clin Infect Dis.* 2005;40:1529-34.
18. Rihn JA, Posfay-Barbe K, Harner CD, Macurak A, Farley A, Greenawalt K, et al. Community-Acquired Methicillin-Resistant *Staphylococcus Aureus* Outbreak in a Local High School Football Team Unsuccessful Interventions. *Pediatr Infect Dis J.* 2005;24:841-3.
19. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. *J Antimicrob Chemother.* 2005;56:455-62.
20. Khoury J, Jones M, Grim A, Dunne WM Jr, Fraser V. Eradication of methicillin-resistant *Staphylococcus aureus* from a neonatal intensive care unit by active surveillance and aggressive infection control measures. *Infect Control Hosp Epidemiol.* 2005;26:616-21.
21. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, et al. The burden of *Staphylococcus aureus* infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. *Arch Intern Med.* 2005;165:1756-61.
22. Chastre J, Fagon JY. Ventilator-associated pneumonia. *Am J Respir Crit Care Med.* 2002;165:867-903.
23. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis.* 2004;39:309-17.
24. Martone WJ, Jarvis WR, Culver DH. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman PS, eds. *Hospital Infections.* Boston: Little Brown; 1992. p. 577-96.
25. Chu VH, Crosslin DR, Friedman JY, Reed SD, Cabell CH, Griffiths RI, et al. *Staphylococcus aureus* bacteremia in patients with prosthetic devices: costs and outcomes. *Am J Med.* 2005;118:1416.
26. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive *Staphylococcus aureus* infections. *J Infect Dis.* 2003;187:1452-9.
27. Mylotte JM, Tayara A. *Staphylococcus aureus* bacteremia: predictors of 30-day mortality in a large cohort. *Clin Infect Dis.* 2000;31:1170-4.
28. Hurst V, Grossman M. The hospital nursery as a source of staphylococcal disease among families of newborn infants. *N Engl J Med.* 1960;262:951-6.
29. Klein JO. Family spread of staphylococcal disease following a nursery outbreak. *N Y State J Med.* 1960;60:861-4.
30. Nahmias AJ, Lepper MH, Hurst V, Mudd S. Epidemiology and treatment of chronic staphylococcal infections in the household. *Am J Public Health.* 1962;52:1828-43.
31. Purcell K, Fergie JE. Exponential increase in community-acquired methicillin-resistant *Staphylococcus aureus* infections in South Texas children. *Pediatr Infect Dis J.* 2002;21:988-9.
32. Pan ES, Diep BA, Carleton HA, Charlebois ED, Sensabaugh GF, Haller BL, et al. Increasing prevalence of methicillin-resistant *Staphylococcus aureus* infection in California jails. *Clin Infect Dis.* 2003;37:1384-8.
33. Creech CB 2nd, Kernodle DS, Alsentzer A, Wilson C, Edwards KM. Increasing rates of nasal carriage of methicillin-resistant *Staphylococcus aureus* in healthy children. *Pediatr Infect Dis J.* 2005;24:617-21.
34. Benenson S, Zimhony O, Dahan D, Solomon M, Raveh D, Schlesinger Y, et al. Atopic dermatitis—a risk factor for invasive *Staphylococcus aureus* infections: two cases and review. *Am J Med.* 2005;118:1048-51.
35. Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev.* 1997;10:505-20.
36. Bibel DJ, Greenberg JH, Cook JL. *Staphylococcus aureus* and the microbial ecology of atopic dermatitis. *Can J Microbiol.* 1977;23:1062-8.
37. Weinstein HJ. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. *N Engl J Med.* 1959;260:1303-8.
38. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. Prospective study of microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. *J Clin Microbiol.* 1988;26:1257-62.
39. Weinke T, Schiller R, Fehrenbach FJ, Pohle HD. Association between *Staphylococcus aureus* nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. *Eur J Clin Microbiol Infect Dis.* 1992;11:985-9.
40. Pujol M, Pena C, Pallares R, Ariza J, Ayats J, Domínguez MA, et al. Nosocomial *Staphylococcus aureus* bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. *Am J Med.* 1996;100:509-16.
41. Cesur S, Cokca F. Nasal carriage of methicillin-resistant *Staphylococcus aureus* among hospital staff and outpatients. *Infect Control Hosp Epidemiol.* 2004;25:169-71.
42. Eveillard M, Martin Y, Hidri N, Boussougant Y, Joly-Guillou ML. Carriage of methicillin-resistant *Staphylococcus aureus* among hospital employees: prevalence, duration, and transmission to households. *Infect Control Hosp Epidemiol.* 2004;25:114-20.
43. Muder RR, Brennen C, Goetz AM. Infection with methicillin-resistant *Staphylococcus aureus* among hospital employees. *Infect Control Hosp Epidemiol.* 1993;14:576-8.
44. Berthelot P, Grattard F, Fascia P, Fichtner C, Moulin M, Lavocat MP, et al. Implication of a healthcare worker with chronic skin disease in the transmission of an epidemic strain of methicillin-resistant *Staphylococcus aureus* in a pediatric intensive care unit. *Infect Control Hosp Epidemiol.* 2003;24:299-300.
45. Blok HE, Troelstra A, Kamp-Hopmans TE, Gigengack-Baars AC, Vandembroucke-Gauls CM, Weersink AJ, et al. Role of healthcare workers in outbreaks of methicillin-resistant *Staphylococcus aureus*: a 10-year evaluation from a Dutch university hospital. *Infect Control Hosp Epidemiol.* 2003;24:679-85.
46. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. *Nature.* 1940;146:837.
47. Gillespie MT, May JW, Skurray RA. Antibiotic resistance in *Staphylococcus aureus* isolated at an Australian hospital between 1946 and 1981. *J Med Microbiol.* 1985;19:137-47.
48. Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD. Antimicrobial resistance in *Staphylococcus aureus* in Australian teaching hospitals, 1989-1999. *Microb Drug Resist.* 2003;9:155-60.
49. Thornsberry C. Trends in antimicrobial resistance among today's bacterial pathogens. *Pharmacotherapy.* 1995;15:3S-8S.
50. Jevons MP. "Celbenin"-resistant staphylococci. *BMJ.* 1961;1:124-5.
51. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: A report from the National Nosocomial Infections Surveillance (NNIS) System. *Am J Infect Control.* 1999;27:79-84.
52. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. *Am J Infect Control.* 2003;31:481-98.
53. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control.* 2004;32:470-85.
54. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. *Am J Infect Control.* 2002;30:458-75.
55. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001. *Am J Infect Control.* 2001;29:404-21.
56. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 *Staphylococcus aureus* isolates from 25 university hospitals participating in the European SENTRY study. *J Clin Microbiol.* 2001;39:3727-32.
57. Boyce JM, Cookson B, Christiansen K, Hori S, Vuopio-Varkila J, Kocagoz S, et al. Methicillin-resistant *Staphylococcus aureus*. *Lancet Infect Dis.* 2005;5:653-63.
58. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant *Staphylococcus aureus* in Europe. *Eur J Clin Microbiol Infect Dis.* 1994;13:50-5.
59. Sista RR, Oda G, Barr J. Methicillin-resistant *Staphylococcus aureus* infections in ICU patients. *Anesthesiol Clin North America.* 2004;22:405-35.
60. Chambers HF. The changing epidemiology of *Staphylococcus aureus*? *Emerg Infect Dis.* 2001;7:178-82.
61. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant *Staphylococcus aureus*: an emerging threat. *Lancet Infect Dis.* 2005;5:275-86.
62. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant *Staphylococcus aureus* disease in three communities. *N Engl J Med.* 2005;352:1436-44.
63. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant *Staphylococcus aureus* infections: a 14-year study at Driscoll Children's Hospital. *Arch Pediatr Adolesc Med.* 2005;159:980-5.

64. Robinson DA, Kearns AM, Holmes A, Morrison D, Grundmann H, Edwards G, et al. Re-emergence of early pandemic *Staphylococcus aureus* as a community-acquired methicillin-resistant clone. *Lancet*. 2005;365:1256-8.
65. Schulz P, Allen M, Murray Q, Smith SA, Goss L, Carrico R, et al. Infections due to community-acquired methicillin-resistant *Staphylococcus aureus*: an emergent epidemic in Kentucky. *J Ky Med Assoc*. 2005;103:194-203.
66. Nguyen DM, Mascola L, Brancoff E. Recurring methicillin-resistant *Staphylococcus aureus* infections in a football team. *Emerg Infect Dis*. 2005;11:526-32.
67. Stemper ME, Shukla SK, Reed KD. Emergence and spread of community-associated methicillin-resistant *Staphylococcus aureus* in rural Wisconsin, 1989 to 1999. *J Clin Microbiol*. 2004;42:5673-80.
68. Campbell KM, Vaughn AF, Russell KL, Smith B, Jiménez DL, Barrozo CP, et al. Risk factors for community-associated methicillin-resistant *Staphylococcus aureus* infections in an outbreak of disease among military trainees in San Diego, California, in 2002. *J Clin Microbiol*. 2004;42:4050-3.
69. Methicillin-resistant *Staphylococcus aureus* infections in correctional facilities—Georgia, California, and Texas, 2001-2003. *MMWR Morb Mortal Wkly Rep*. 2003;52:992-6.
70. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clin Infect Dis*. 1999;29:1128-32.
71. Diep BA, Sensabaugh GF, Somboona NS, Carleton HA, Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant *Staphylococcus aureus* strains harboring the genes for Panton-Valentine leukocidin. *J Clin Microbiol*. 2004;42:2080-4.
72. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant *Staphylococcus aureus* carrying the Panton-Valentine leukocidin genes. *Clin Infect Dis*. 2005;40:100-7.
73. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, et al. Emergence of community-associated methicillin-resistant *Staphylococcus aureus* USA300 genotype as a major cause of health care-associated blood stream infections. *Clin Infect Dis*. 2006;42:647-56.
74. Austin TW, Austin MA, Coleman B. Methicillin-resistant/methicillin-sensitive *Staphylococcus aureus* bacteremia. *Saudi Med J*. 2003;24:256-60.
75. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. *Arch Intern Med*. 2002;162:2229-35.
76. Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of *Staphylococcus aureus* bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. *Medicine (Baltimore)*. 2003;82:322-32.
77. Combes A, Trouillet JL, Joly-Guillou ML, Chastre J, Gibert C. The impact of methicillin resistance on the outcome of poststernotomy mediastinitis due to *Staphylococcus aureus*. *Clin Infect Dis*. 2004;38:822-9.
78. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in *Staphylococcus aureus* bacteremia on patient outcomes: mortality, length of stay, and hospital charges. *Infect Control Hosp Epidemiol*. 2005;26:166-74.
79. Cowie SE, Ma I, Lee SK, Smith RM, Hsiang YN. Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome. *Vasc Endovascular Surg*. 2005;39:327-34.
80. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with *Staphylococcus aureus* surgical site infection. *Clin Infect Dis*. 2003;36:592-8.
81. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by *Staphylococcus aureus*. *Arch Intern Med*. 1998;158:182-9.
82. Hershov RC, Khayr WF, Smith NL. A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* infections in a university hospital. *Infect Control Hosp Epidemiol*. 1992;13:587-93.
83. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant *Staphylococcus aureus* infections. *Ann Pharmacother*. 2004;38:1377-82.
84. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with *Staphylococcus aureus* bacteremia. *Diagn Microbiol Infect Dis*. 2005;52:113-22.
85. Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* musculoskeletal infections in children. *Pediatr Infect Dis J*. 2004;23:701-6.
86. Marty L, Flahault A, Suarez B, Caillon J, Hill C, Andreumont A. Resistance to methicillin and virulence of *Staphylococcus aureus* strains in bacteriemic cancer patients. *Intensive Care Med*. 1993;19:285-9.
87. Mekontso-Dessap A, Kirsch M, Brun-Buisson C, Loïsan D. Poststernotomy mediastinitis due to *Staphylococcus aureus*: comparison of methicillin-resistant and methicillin-susceptible cases. *Clin Infect Dis*. 2001;32:877-83.
88. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant *Staphylococcus aureus* more virulent than methicillin-susceptible *S. aureus*? A comparative cohort study of British patients with nosocomial infection and bacteremia. *Clin Infect Dis*. 2003;37:1453-60.
89. Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KJ, Kaye KS, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible *Staphylococcus aureus* bacteremia. *Infect Control Hosp Epidemiol*. 2005;26:175-83.
90. Romero-Vivas J, Rubio M, Fernández C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis*. 1995;21:1417-23.
91. Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant *Staphylococcus aureus* bacteremia: is it any worse than nosocomial methicillin-sensitive *Staphylococcus aureus* bacteremia? *Infect Control Hosp Epidemiol*. 2000;21:645-8.
92. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant *Staphylococcus aureus* bacteraemia: a meta-analysis. *Med J Aust*. 2001;175:264-7.
93. Yoon HJ, Choi JY, Kim CO, Kim JM, Song YG. A comparison of clinical features and mortality among methicillin-resistant and methicillin-sensitive strains of *Staphylococcus aureus* endocarditis. *Yonsei Med J*. 2005;46:496-502.
94. Zahar JR, Clech C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, et al. Is methicillin resistance associated with a worse prognosis in *Staphylococcus aureus* ventilator-associated pneumonia? *Clin Infect Dis*. 2005;41:1224-31.
95. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant *Staphylococcus aureus* containing the vanA resistance gene. *N Engl J Med*. 2003;348:1342-7.
96. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J Antimicrob Chemother*. 1997;40:135-6.
97. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant *Staphylococcus aureus* strain Mu50. *J Antimicrob Chemother*. 1998;42:315-20.
98. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant *Staphylococcus aureus* infection. *N Engl J Med*. 1999;340:517-23.
99. Noble MC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *FEMS Microbiol Lett*. 1992;93:195-8.
100. Nagel JG, Sheagren JN, Tuazon CU, Cardella TA. Teichoic acids in pathogenic *Staphylococcus aureus*. *J Clin Microbiol*. 1977;6:233-7.
101. Kloos WE, Musselwhite MS. Distribution and persistence of *Staphylococcus* and *Micrococcus* species and other aerobic bacteria on human skin. *Appl Microbiol*. 1975;30:381-5.
102. McDevitt D, Vaudaux P, Foster TJ. Genetic evidence that bound coagulase of *Staphylococcus aureus* is not clumping factor. *Infect Immun*. 1992;60:1514-23.
103. Drew WL, Barry AL, O'Toole R, Sherris JC. Reliability of the Kirby-Bauer disc diffusion method for detecting methicillin-resistant strains of *Staphylococcus aureus*. *Appl Microbiol*. 1972;24:240-7.
104. Barry AL, Badal RE. Reliability of the microdilution technic for detection of methicillin-resistant strains of *Staphylococcus aureus*. *Am J Clin Pathol*. 1977;67:489-95.
105. Hagen RM, Seegmuller I, Navai J, Kappstein I, Lehn N, Miethke T. Development of a real-time PCR assay for rapid identification of methicillin-resistant *Staphylococcus aureus* from clinical samples. *Int J Med Microbiol*. 2005;295:77-86.
106. Huletsky A, Lebel P, Picard FJ, Bernier M, Gagnon M, Boucher N, et al. Identification of methicillin-resistant *Staphylococcus aureus* carriage in less than 1 hour during a hospital surveillance program. *Clin Infect Dis*. 2005;40:976-81.
107. Paule SM, Pasquariello AC, Thomson RB Jr, Kaul KL, Peterson LR. Real-time PCR can rapidly detect methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* directly from positive blood culture bottles. *Am J Clin Pathol*. 2005;124:404-7.
108. Deurenberg RH, Vink C, Driessen C, Bes M, London N, Rtiene J, et al. Rapid detection of Panton-Valentine leukocidin from clinical isolates of *Staphylococcus aureus* strains by real-time PCR. *FEMS Microbiol Lett*. 2004;240:225-8.
109. McDonald RR, Antonishyn NA, Hansen T, Snook LA, Nagle E, Mulvey MR, et al. Development of a triplex real-time PCR assay for detection of Panton-Valentine leukocidin toxin genes in clinical isolates of methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol*. 2005;43:6147-9.

110. Pfaller MA, Wakefield DS, Hollis R, Fredrickson M, Evans E, Massanari RM. The clinical microbiology laboratory as an aid in infection control. The application of molecular techniques in epidemiologic studies of methicillin-resistant *Staphylococcus aureus*. *Diagn Microbiol Infect Dis*. 1991;14:209-17.
111. Branchini ML, Morthland VH, Tresoldi AT, Von Nowakonsky A, Dias MB, Pfaller MA. Application of genomic DNA subtyping by pulsed field gel electrophoresis and restriction enzyme analysis of plasmid DNA to characterize methicillin-resistant *Staphylococcus aureus* from two nosocomial outbreaks. *Diagn Microbiol Infect Dis*. 1993;17:275-81.
112. Van Belkum A, Bax R, Peerbooms P, Goossens WH, Van Leeuwen N, Quint WG. Comparison of phage typing and DNA fingerprinting by polymerase chain reaction for discrimination of methicillin-resistant *Staphylococcus aureus* strains. *J Clin Microbiol*. 1993;31:798-803.
113. Ryding U, Espersen F, Soderquist B, Christensson B. Evaluation of seven different enzyme-linked immunosorbent assays for serodiagnosis of *Staphylococcus aureus* bacteremia. *Diagn Microbiol Infect Dis*. 2002;42:9-15.
114. Wise KA, Tosolini FA. Detection of teichoic acid antibodies in *Staphylococcus aureus* infections. *Pathology*. 1992;24:102-8.
115. Crossley KB, Archer GL, eds. The staphylococci in human disease. New York: Churchill Livingstone; 1997.
116. Verhoef J, Fluit AC, Schmitz FJ. Staphylococci and other Micrococceae. In: Cohen J, Powderly WG, eds. Infectious diseases. Philadelphia: Elsevier; 2004. p. 2119-32.
117. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med*. 2002;137:791-7.
118. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to *Staphylococcus aureus*: evaluation of different clinical case definitions. *Clin Infect Dis*. 1993;16:567-73.
119. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of *Staphylococcus aureus* bacteremia. *Rev Infect Dis*. 1987;9:891-907.
120. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired *Staphylococcus aureus* bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. *Clin Infect Dis*. 1996;23:255-9.
121. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. *Am J Med*. 1991;91:S86-9.
122. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. *Clin Infect Dis*. 1999;29:239-44.
123. Lyytikäinen O, Ruotsalainen E, Jarvinen A, Valtonen V, Ruutu P. Trends and outcome of nosocomial and community-acquired bloodstream infections due to *Staphylococcus aureus* in Finland, 1995-2001. *Eur J Clin Microbiol Infect Dis*. 2005;24:399-404.
124. Holmes A, Ganner M, McGuane S, Pitt TL, Cookson BD, Kearns AM. *Staphylococcus aureus* isolates carrying Pantone-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. *J Clin Microbiol*. 2005;43:2384-90.
125. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Pantone-Valentine leucocidin-positive community-acquired methicillin-resistant *Staphylococcus aureus*: importance of treatment with antimicrobials inhibiting exotoxin production. *Chest*. 2005;128:2732-8.
126. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant *Staphylococcus aureus* in Los Angeles. *N Engl J Med*. 2005;352:1445-53.
127. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant *Staphylococcus aureus*: perspectives on measures needed for control. *Ann Intern Med*. 1996;124:329-34.
128. Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, et al. Outcome of *Staphylococcus aureus* bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. *Clin Infect Dis*. 1998;27:478-86.
129. Libman H, Arbeit RD. Complications associated with *Staphylococcus aureus* bacteremia. *Arch Intern Med*. 1984;144:541-5.
130. Mirimani RO, Glauser MP. Endocarditis during *Staphylococcus aureus* septicemia in a population of non-drug addicts. *Arch Intern Med*. 1982;142:1311-3.
131. Ringberg H, Thoren A, Lilja B. Metastatic complications of *Staphylococcus aureus* septicemia. To seek is to find. *Infection*. 2000;28:132-6.
132. Espersen F, Fridmott-Moller N. *Staphylococcus aureus* endocarditis. A review of 119 cases. *Arch Intern Med*. 1986;146:1118-21.
133. Lamas CC, Eykyn SJ. Bicuspid aortic valve—A silent danger: analysis of 50 cases of infective endocarditis. *Clin Infect Dis*. 2000;30:336-41.
134. Wilson R, Hamburger M. Fifteen years' experience with staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. *Am J Med*. 1957;22:437-57.
135. Chamis AL, Peterson GE, Cabell CH, Corey GR, Sorrentino RA, Greenfield RA, et al. *Staphylococcus aureus* bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. *Circulation*. 2001;104:1029-33.
136. Fang G, Keys TF, Gentry LO, Harris AA, Rivera N, Getz K, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. *Ann Intern Med*. 1993;119:560-7.
137. Murdoch DR, Roberts SA, Fowler VG Jr, Shah MA, Taylor SL, Morris AJ, et al. Infection of orthopedic prostheses after *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2001;32: 647-9.
138. Nolan CM, Beaty HN. *Staphylococcus aureus* bacteremia. Current clinical patterns. *Am J Med*. 1976;60:495-500.
139. Willcox PA, Rayner BL, Whitelaw DA. Community-acquired *Staphylococcus aureus* bacteraemia in patients who do not abuse intravenous drugs. *QJM*. 1998;91:41-7.
140. Werner GS, Schulz R, Fuchs JB, Andreas S, Prange H, Ruschewski W, et al. Infective endocarditis in the elderly in the era of transesophageal echocardiography: clinical features and prognosis compared with younger patients. *Am J Med*. 1996;100:90-7.
141. Marr KA, Kong L, Fowler VG, Gopal A, Sexton DJ, Coulon PJ, et al. Incidence and outcome of *Staphylococcus aureus* bacteremia in hemodialysis patients. *Kidney Int*. 1998;54:1684-9.
142. Jacobson MA, Gellermann H, Chambers H. *Staphylococcus aureus* bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. *Am J Med*. 1988;85:172-6.
143. Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated *Staphylococcus aureus* bacteremia. *Arch Intern Med*. 2003;163:2066-72.
144. Miro JM, Anguera I, Cabell CH, Chen AY, Shafford JA, Corey GR, et al. *Staphylococcus aureus* native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. *Clin Infect Dis*. 2005;41:507-14.
145. Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ, et al. Changing patient characteristics and the effect on mortality in endocarditis. *Arch Intern Med*. 2002;162:90-4.
146. Fernandez-Guerrero ML, Verdejo C, Azofra J, De Gorgolas M. Hospital-acquired infective endocarditis not associated with cardiac surgery: an emerging problem. *Clin Infect Dis*. 1995;20:16-23.
147. Sanabria TJ, Alpert JS, Goldberg R, Pape LA, Cheeseman SH. Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988. *Arch Intern Med*. 1990;150:1305-9.
148. Watanakunakorn C, Burkert T. Infective endocarditis at a large community teaching hospital, 1980-1990. A review of 210 episodes. *Medicine (Baltimore)*. 1993;72:90-102.
149. Fowler VG Jr, Sanders LL, Kong LK, McClelland RS, Gottlieb GS, Li J, et al. Infective endocarditis due to *Staphylococcus aureus*: 59 prospectively identified cases with follow-up. *Clin Infect Dis*. 1999;28:106-14.
150. Saiman L, Prince A, Gersony WM. Pediatric infective endocarditis in the modern era. *J Pediatr*. 1993;122:847-53.
151. Watanakunakorn C. *Staphylococcus aureus* endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. *Arch Intern Med*. 1994;154:2330-5.
152. Roder BL, Wandall DA, Fridmott-Moller N, Espersen F, Skinhoj P, Rosdahl VT. Clinical features of *Staphylococcus aureus* endocarditis: a 10-year experience in Denmark. *Arch Intern Med*. 1999;159:462-9.
153. Mugge A. Echocardiographic detection of cardiac valve vegetations and prognostic implications. *Infect Dis Clin North Am*. 1993;7:877-98.
154. Chamis AL, Gesty-Palmer D, Fowler VG, Corey GR. Echocardiography for the Diagnosis of *Staphylococcus aureus* Infective Endocarditis. *Curr Infect Dis Rep*. 1999;1:129-35.
155. Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, Nonnast-Daniel B, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. *N Engl J Med*. 1991;324:795-800.
156. De Castro S, d'Amati G, Cartoni D, Venditti M, Magni G, Gallo P, et al. Valvular perforation in left-sided infective endocarditis: a prospective echocardiographic evaluation and clinical outcome. *Am Heart J*. 1997;134:656-64.
157. Habib G, Guidon C, Tricoire E, Djiane V, Monties JR, Luccioni R. Papillary muscle rupture caused by bacterial endocarditis: role of transesophageal echocardiography. *J Am Soc Echocardiogr*. 1994;7:79-81.
158. Lowry RW, Zoghbi WA, Baker WB, Wray RA, Quinones MA. Clinical impact of transesophageal echocardiography in the diagnosis and management of infective endocarditis. *Am J Cardiol*. 1994;73:1089-91.
159. Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. *J Am Coll Cardiol*. 1993;21:216-21.
160. DiNubile MJ. Skepticism: a lost clinical art. *Clin Infect Dis*. 2000;31:513-8.
161. Heidenreich PA, Masoudi FA, Maini B, Chou TM, Foster E, Schiller NB, et al. Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis. *Am J Med*. 1999;107:198-208.

162. Lindner JR, Case RA, Dent JM, Abbott RD, Scheld WM, Kaul S. Diagnostic value of echocardiography in suspected endocarditis. An evaluation based on the pretest probability of disease. *Circulation*. 1996;93:730-6.
163. Rosen AB, Fowler VG Jr, Corey GR, Downs SM, Biddle AK, Li J, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated *Staphylococcus aureus* bacteremia. *Ann Intern Med*. 1999;130:810-20.
164. Arnett EN, Roberts WC. Valve ring abscess in active infective endocarditis. Frequency, location, and clues to clinical diagnosis from the study of 95 necropsy patients. *Circulation*. 1976;54:140-5.
165. Omari B, Shapiro S, Ginzton L, Robertson JM, Ward J, Nelson RJ, et al. Predictive risk factors for periannular extension of native valve endocarditis. Clinical and echocardiographic analyses. *Chest*. 1989;96:1273-9.
166. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. *Arch Intern Med*. 2000;160:2781-7.
167. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT. Neurologic manifestations in *Staphylococcus aureus* endocarditis: a review of 260 bacteremic cases in nondrug addicts. *Am J Med*. 1997;102:379-86.
168. Tak T, Reed KD, Haselby RC, McCauley CS Jr, Shukla SK. An update on the epidemiology, pathogenesis and management of infective endocarditis with emphasis on *Staphylococcus aureus*. *WJ*. 2002;101:24-33.
169. Gonzalez C, Rubio M, Romero-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to *Staphylococcus aureus*: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. *Clin Infect Dis*. 1999;29:1171-7.
170. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. *Crit Care Med*. 1999;27:887-92.
171. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. *Eur J Clin Microbiol Infect Dis*. 1996;15:281-5.
172. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171:388-416.
173. Iwahara T, Ichiyama S, Nada T, Shimokata K, Nakashima N. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin-resistant *Staphylococcus aureus*. *Chest*. 1994;105:826-31.
174. Rello J, Torres A, Ricart M, Vallés J, González J, Artigas A, et al. Ventilator-associated pneumonia by *Staphylococcus aureus*. Comparison of methicillin-resistant and methicillin-sensitive episodes. *Am J Respir Crit Care Med*. 1994;150:1545-9.
175. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant *Staphylococcus aureus*—Minnesota and North Dakota, 1997-1999. *JAMA*. 1999;282:1123-5.
176. Boussaud V, Parrot A, Mayaud C, Wislez M, Antoine M, Picard C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Pantone-Valentine leukocidin-secreting *Staphylococcus aureus*. *Intensive Care Med*. 2003;29:1840-3.
177. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association between *Staphylococcus aureus* strains carrying gene for Pantone-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. *Lancet*. 2002;359:753-9.
178. González BE, Martínez-Aguilar G, Hultén KG, Hammerman WA, Coss-Bu J, Avalos-Mishaan A, et al. Severe *Staphylococcal* sepsis in adolescents in the era of community-acquired methicillin-resistant *Staphylococcus aureus*. *Pediatrics*. 2005;115:642-8.
179. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe *Staphylococcus aureus* infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. *Clin Infect Dis*. 2003;37:1050-8.
180. Macfarlane J, Rose D. Radiographic features of staphylococcal pneumonia in adults and children. *Thorax*. 1996;51:539-40.
181. Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. *Semin Respir Infect*. 1990;5:260-8.
182. Tsokos M, Zollner B, Feucht HH. Fatal influenza A infection with *Staphylococcus aureus* superinfection in a 49-year-old woman presenting as sudden death. *Int J Legal Med*. 2005;119:40-3.
183. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. *Ann Intern Med*. 1992;117:560-6.
184. Naraqi S, McDonnell G. Hematogenous staphylococcal pneumonia secondary to soft tissue infection. *Chest*. 1981;79:173-5.
185. Moise PA, Schentag JJ. Vancomycin treatment failures in *Staphylococcus aureus* lower respiratory tract infections. *Int J Antimicrob Agents*. 2000;16 Suppl 1:31-4.
186. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *J Clin Microbiol*. 2004;42:2398-402.
187. Jones RN, Ballou CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. *Diagn Microbiol Infect Dis*. 1998;31:437-51.
188. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. *Synercid Skin and Skin Structure Infection Group*. *J Antimicrob Chemother*. 1999;44:263-73.
189. Raad I, Bompard F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. *Eur J Clin Microbiol Infect Dis*. 1999;18:199-202.
190. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. *Nosocomial Pneumonia Group*. *Am J Respir Crit Care Med*. 2000;161:753-62.
191. Mouton JW, Endtz HP, Den Hollander JG, van den Braak N, Verbrugh HA. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. *J Antimicrob Chemother*. 1997;39 Suppl A:75-80.
192. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to *Staphylococcus aureus* constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. *Antimicrob Agents Chemother*. 2000;44:1789-95.
193. Batard E, Jacqueline C, Boutoille D, Hamel A, Drugeon HB, Asseray N, et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant *Staphylococcus aureus*: experimental rabbit endocarditis study. *Antimicrob Agents Chemother*. 2002;46:2174-8.
194. Zarrouk V, Bozdogan B, Leclercq R, Garry L, Feger C, Carbon C, et al. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to *Staphylococcus aureus* strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. *Antimicrob Agents Chemother*. 2001;45:1244-8.
195. Pavie J, Lefort A, Zarrouk V, Chau F, Garry L, Leclercq R, et al. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant *Staphylococcus aureus* in relation to cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics. *Antimicrob Agents Chemother*. 2002;46:3061-4.
196. Drew RH, Perfect JR, Srinath L, Kurkimiis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant *Staphylococcus aureus* infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. *J Antimicrob Chemother*. 2000;46:775-84.
197. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. *Antimicrob Agents Chemother*. 2002;46:1319-24.
198. Olsen KM, Rebeck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. *Clin Infect Dis*. 2001;32:e83-6.
199. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. *Drugs*. 2001;61:525-51.
200. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. *Antimicrob Agents Chemother*. 2005;49:2260-6.
201. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. *Intensive Care Med*. 2004;30:388-94.
202. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia. *Chest*. 2003;124:1789-97.
203. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for *Staphylococcus aureus* bacteraemia: pooled analysis of randomized studies. *J Antimicrob Chemother*. 2005;56:923-9.
204. Bassetti M, Di Biagio A, Del Bono V, Cenderello G, Bassetti D. Successful treatment of methicillin-resistant *Staphylococcus aureus* endocarditis with linezolid. *Int J Antimicrob Agents*. 2004;24:83-4.
205. Nathani N, Iles P, Elliott TS. Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report. *J Infect*. 2005;51:e213-5.
206. Souli M, Pontikis K, Chryssouli Z, Galani I, Giamarellou H. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant *Staphylococcus aureus* with linezolid. *Eur J Clin Microbiol Infect Dis*. 2005;24:760-2.
207. Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant *Staphylococcus aureus* endocarditis with linezolid. *Scand J Infect Dis*. 2005;37:946-9.

208. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant *Staphylococcus aureus*: treatment failure with linezolid. *Clin Infect Dis*. 2002;35:1018-20.
209. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. *Clin Infect Dis*. 2004;38:1673-81.
210. Cohen MA, Docktor JW. Acute suppurative parotitis with spread to the deep neck spaces. *Am J Emerg Med*. 1999;17:46-9.
211. Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant *Staphylococcus aureus* prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. *Heart Lung*. 2005;34:69-71.
212. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. *J Infect Dis*. 2005;191:2149-52.
213. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. *Am J Health Syst Pharm*. 2005;62:1145-58.
214. Noskin GA. Tigecycline: a new glycylicline for treatment of serious infections. *Clin Infect Dis*. 2005;41 Suppl 5:303-14.
215. Rubinstein E, Vaughan D. Tigecycline: a novel glycylicline. *Drugs*. 2005;65:1317-36.
216. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. *Clin Infect Dis*. 2005;41:1407-15.
217. Raad I, Darouiche R, Vázquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. *Clin Infect Dis*. 2005;40:374-80.
218. Hegde SS, Reyes N, Wiens T, Vanasse M, Skinner R, McCullough J, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. *Antimicrob Agents Chemother*. 2004;48:3043-50.
219. Reyes N, Skinner R, Kaniga K, Krause KM, Shelton J, Obenedino GP, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2005;49:4344-6.
220. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant *Staphylococcus aureus* or vancomycin-intermediate *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2005;49:3163-5.
221. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. *Clin Infect Dis*. 2005;40:1601-7.
222. Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A. Vaccination with a recombinant fragment of collagen adhesin provides protection against *Staphylococcus aureus*-mediated septic death. *J Clin Invest*. 1998;101:2640-9.
223. Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant *Staphylococcus aureus* bacteremia in an experimental model of infective endocarditis. *Antimicrob Agents Chemother*. 2003;47:3400-6.
224. Weems JJ, Steinberg JP, Filler S, et al. A Phase II, randomized, double-blind, multi-center clinical trial comparing safety and pharmacokinetics of standard of care, plus tefibazumab or placebo, for treatment of *Staphylococcus aureus* bacteremia. Abstract: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2005.
225. Kluytmans JA, Mouton JW, VandenBergh MF, Manders MJ, Maat AP, Wagenvoort JH, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of *Staphylococcus aureus*. *Infect Control Hosp Epidemiol*. 1996;17:780-5.
226. Kalmeijer MD, Coertjens H, Van Nieuwland-Bollen PM, Bogaers-Hofman D, De Baere GA, Stuurman A, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. *Clin Infect Dis*. 2002;35:353-8.
227. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, et al. Intranasal mupirocin to prevent postoperative *Staphylococcus aureus* infections. *N Engl J Med*. 2002;346: 1871-7.
228. Boelaert JR, De Smedt RA, De Baere YA, Godard CA, Mathys EG, Schurgers ML, et al. The influence of calcium mupirocin nasal ointment on the incidence of *Staphylococcus aureus* infections in haemodialysis patients. *Nephrol Dial Transplant*. 1989;4:278-81.
229. Wertheim HF, Vos MC, Ott A, Voss A, Kluytmans JA, Vandenbroucke-Grauls CM, et al. Mupirocin prophylaxis against nosocomial *Staphylococcus aureus* infections in nonsurgical patients: a randomized study. *Ann Intern Med*. 2004;140:419-25.
230. Kluytmans JA, Wertheim HF. Nasal carriage of *Staphylococcus aureus* and prevention of nosocomial infections. *Infection*. 2005;33:3-8.
231. Fawley WN, Parnell P, Hall J, Wilcox MH. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. *J Hosp Infect*. 2005.
232. Hurdle JG, O'Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from *Staphylococcus epidermidis* to methicillin-resistant *Staphylococcus aureus* associated with failure of mupirocin prophylaxis. *J Antimicrob Chemother*. 2005;56:1166-8.
233. Vastag B. New vaccine decreases rate of nosocomial infections. *JAMA*. 2001;285:1565-6.
234. Garner JS. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. *Am J Infect Control*. 1996;24:24-31.
235. Boyce JM, Havill NL, Kohan C, Dumigan DG, Ligi CE. Do infection control measures work for methicillin-resistant *Staphylococcus aureus*? *Infect Control Hosp Epidemiol*. 2004;25:395-401.
236. Cosseron-Zerbib M, Roque Afonso AM, Naas T, Durand P, Meyer L, Costa Y, et al. A control programme for MRSA (methicillin-resistant *Staphylococcus aureus*) containment in a paediatric intensive care unit: evaluation and impact on infections caused by other micro-organisms. *J Hosp Infect*. 1998;40:225-35.
237. Eveillard M, Eb F, Tramier B, Schmit JL, Lescure FX, Biendo M, et al. Evaluation of the contribution of isolation precautions in prevention and control of multi-resistant bacteria in a teaching hospital. *J Hosp Infect*. 2001;47:116-24.
238. Raboud J, Saskin R, Simor A, Loeb M, Green K, Low DE, et al. Modeling transmission of methicillin-resistant *Staphylococcus aureus* among patients admitted to a hospital. *Infect Control Hosp Epidemiol*. 2005;26:607-15.
239. Schelenz S, Tucker D, Georgeu C, Daly S, Hill M, Roxburgh J, et al. Significant reduction of endemic MRSA acquisition and infection in cardiothoracic patients by means of an enhanced targeted infection control programme. *J Hosp Infect*. 2005;60:104-10.
240. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant *Staphylococcus aureus* (MRSA) carriers in the context of diagnosis related groups (DRG) payment. *Clin Microbiol Infect*. 2005;11:466-71.
241. Berhe M, Edmond MB, Bearman GM. Practices and an assessment of health care workers' perceptions of compliance with infection control knowledge of nosocomial infections. *Am J Infect Control*. 2005;33:55-7.
242. Cromer AL, Hutsell SO, Latham SC, Garcia-Valdecasas J, Gorritz JL, Soriano A, et al. Impact of implementing a method of feedback and accountability related to contact precautions compliance. *Am J Infect Control*. 2004;32:451-5.
243. Kermode M, Jolley D, Langkham B, Thomas MS, Holmes W, Gifford SM. Compliance with Universal/Standard Precautions among health care workers in rural north India. *Am J Infect Control*. 2005;33:27-33.
244. Aragon D, Sole ML, Brown S. Outcomes of an infection prevention project focusing on hand hygiene and isolation practices. *AACN Clin Issues*. 2005;16:121-32.
245. Arenas MD, Sanchez-Paya J, Barril G, Grel G, Senol YY, Turhan O, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. *Nephrol Dial Transplant*. 2005;20:1164-71.
246. Kuzu N, Ozer F, Aydemir S, Yalcin AN, Zencir M. Compliance with hand hygiene and glove use in a university-affiliated hospital. *Infect Control Hosp Epidemiol*. 2005;26:312-5.
247. Saba R, Inan D, Seyman D, et al. Hand hygiene compliance in a hematology unit. *Acta Haematol*. 2005;113:190-3.